

8-w induction therapy and 44-week maintenance in mod-severe UC.
Both double-blind, placebo controlled trials.
UST IV induction vs placebo.
Responders re-randomized to: UST sc 90 mg q12w or 18w or placebo.

Primary endpoint for induction trial and maintenance trial: clinical remission w 8 and w44

Results:

- Clinical remission w8 after UST IV superior than placebo (15.6% vs 5.3%, $p < 0.001$).
- Among responders with second randomization, clinical remission w44: UST 90mg q12w (38.2%) vs UST q8w (43.8%) vs placebo (24%), $p = 0.002$ and $p > 0.001$ respectively.

Conclusions:

Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe UC.

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

